The Glycemic Research Institute Certification Marks are available
for use on products that meet the criteria of Glycemic Research
Institute’s protocol, per FDA and FTC guidelines on Food,
Nutraceutical, and Pharmaceutical labels, as marketed to the general
public.
“LOW GLYCEMIC” CERTIFICATION
The Low Glycemic Certification Seal/Mark may only be used on products
that have been clinically proven to be “Low Glycemic with
a Low Glycemic load when fed to non-diabetic humans.”
“LOW GLYCEMIC for DIABETICS”CERTIFICATION
The Low Glycemic for Diabetics Certification Seal/Mark may only
be used on products that have been clinically proven to be “Low
Glycemic with a Low Glycemic Load when fed to Type II human diabetics.”
Diabetic trials must utilize diabetic patients, including outliers.
In Vitro studies are not accepted, nor are software-derived glycemic
indices.
"KID
FRIENDLY" CERTIFICATION
The Kid Friendly Certification Seal/Mark may only be used on Child-Friendly
products that have been clinically proven to meet the criteria
for KID FRIENDLY FOODS.
"LOW GLYCEMIC" LATIN CERTIFICATION
New Certification Seal for the Latin Market
Click
Link to read PRESS RELEASE
REQUIREMENTS
FOR LICENSING |
APPROVED
HUMAN IN VIVO CLINICAL TRIALS
GRI
Approved Human In Vivo Clinical Trials (HVCT)
|
Submission of products must be accompanied by valid HVCT. Products
that are not accompanied by government approved clinical trial
protocols will not be approved to use the GRI Certification Marks.
Products
that have not yet been tested in HVCT can submit their product
(s) to the Official Glycemic Index Testing Facility:
GLYCEMIC INDEX TESTING
A Clinical Studies Coordinator (CSC) will be assigned to each
client. The CSC will guide the client through each step of the
process, from Application to final Official Glycemic Report and
use of the Certification Marks. Fee Schedules will be provided
by Glycemic Solutions upon request.
For more information on these programs, please go to: www.GlycemicIndexTesting.com
APPLYING
for CERTIFICATION MARKS |
To
be licensed to use the Glycemic Research Institute Certification
Marks, click the following link to download:
The
Glycemic Research Institute (GRI) Certification Marks are
Federally protected registered Marks based on more than 20+
years of Glycemic Human In Vivo Clinical Testing with a error
rate (variable) of less than 2 % (the lowest in the industry
worldwide). |
USA CERTIFICATION
Authorized and Registered
United States Federal Government Certification
CANADA CERTIFICATION
Authorized and Registered
Canadian Government Certification
UNITED
KINGDOM CERTIFICATION
Authorized and Registered
United Kingdom Government Certification
INDIA CERTIFICATION
In 2008, GRI opened its newest branch in India. Food
companies in India may now submit products for Human In Vivo clinical
trials. (www.Glycemic.in)
GLOBAL
TESTING PROTOCOLS & STANDARDS:
WORLD HEALTH ORGANIZATION (WHO)
FOOD and AGRICULTURE ORGANIZATION of the UNITED NATIONS (FAO)
ACCEPTABLE
TESTING PROTOCOLS |
The Glycemic Research Institute (GRI) “Low Glycemic”
testing protocols have been duly submitted to various worldwide
governments.
GRI clinical testing protocols adhere to the World Health Organization
(WHO), FDA and FTC guidelines and as specified by Standardized Clinical
Testing Protocols accepted in the United States and worldwide, as
required for substantiation of validity for “Low Glycemic”
claims as pertaining to Test Foods analyzed.
The
Food and Agriculture Organization of the United Nations
(FAO) states that:
“People
in industrialized countries base their diets on Low Glycemic
Index (GI) foods in order to prevent the most common diseases
of affluence, such as coronary heart disease, diabetes and
obesity.”
“In
1997 a committee of experts was brought together by the Food
and Agriculture Organization (FAO) of the United Nations and
the World Health Organization (WHO) to review the available
research evidence regarding the importance of carbohydrates
in human nutrition and health.
The
committee endorsed the use of the GI method for classifying
carbohydrate-rich foods and recommended that the GI values
of foods be used in conjunction with information about food
composition to guide food choices.
To
promote good health, the committee advocated the consumption
of a high-carbohydrate diet ( 55% of energy from carbohydrate),
with the bulk of carbohydrate-containing foods being rich
in nonstarch polysaccharides with a low GI”.
Reference: American Journal of Clinical Nutrition,
Vol. 76, No. 1, 5-56, 2002 © 2002 American Society for
Clinical Nutrition
|
The
World Health Organization and the FAO recommends that current
food labeling terms for carbohydrates and sugars have “little
nutritional or physiological significance” and instead recommend:
•
The glycemic index rating for a food “Must be
tested physiologically (Human
Glycemic In Vivo Clinical Trials) at
a legitimate clinical testing facility.”
•
Carbohydrate and sugar labeling terms be removed and replaced
with Total Carbohydrate content of the food
and its Glycemic Value.
|
USE
OF THE GRI CERTIFICATION MARKS |
The
Glycemic Research Institute (GRI) name and Certification Marks are
Federal government registered marks of GRI.
The GRI Marks belong solely to the Glycemic Research Institute for
use in certifying edible goods such as
foods, drinks, Nutraceuticals, and Pharmaceuticals, and may not
be used or displayed in any format without a license from GRI.
The GRI Marks may only be used by GRI certified companies with the
express written permission of GRI.
All packaging and materials using the GRI Certification Marks must
be approved by GRI prior to printing, sale, or distribution.
Sale and/or marketing of products with “Low Glycemic”
claims that have not undergone Board Approved Human
In Vivo Clinical Trials is a violation of Federal
government laws and can result in federal and state liability and
fines and/or enforcement action.
The Federal government and its associated agencies, such as the
FDA and the FTC, require very specific clinical trials to be conducted
in order to make a claim of “Low Glycemic” within the
borders of the United States.
Acceptable protocols require human In Vivo clinical trials utilizing
FDA-appropriate serving sizes, low-variable glycemic index and load
studies. The clinical study and protocol must be IRB approved and
well as state approved.
|
